ATC Group: N06D Anti-dementia drugs

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06D in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06D Anti-dementia drugs

Group N06D contents

Code Title
N06DA Anticholinesterases
N06DX Other anti-dementia drugs

Active ingredients in N06D

Active Ingredient

Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. Donanemab-azbt reduces amyloid beta plaques, as evaluated in Study 1.

Donepezil hydrochloride is a specific and reversible inhibitor of acetylcholinesterase, the predominant cholinesterase in the brain. Donepezil hydrochloride is in vitro over 1000 times more potent an inhibitor of this enzyme than of butyrylcholinesterase, an enzyme that is present mainly outside the central nervous system.

Galantamine, a tertiary alkaloid is a selective, competitive and reversible inhibitor of acetylcholinesterase. In addition, galantamine enhances the intrinsic action of acetylcholine on nicotinic receptors, probably through binding to an allosteric site of the receptor. As a consequence, an increased activity in the cholinergic system associated with improved cognitive function can be achieved in patients with dementia of the Alzheimer type.

The exact mechanism of action of ginkgo biloba is not known. Human pharmacological data show increased EEG vigilance in geriatric subjects, reduction in blood viscosity and improved cerebral perfusion in specific areas in healthy men (60-70 years) and reduction in platelet aggregation. Additionally, vasodilating effects on forearm blood vessels causing increased regional blood flow are shown.

Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. Lecanemab reduces amyloid beta plaques, as evaluated in studies.

Memantine is a voltage-dependent, moderate-affinity uncompetitive NMDA-receptor antagonist. It modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.

Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones. Thus, rivastigmine may have an ameliorative effect on cholinergic-mediated cognitive deficits in dementia associated with Alzheimer’s disease and Parkinson’s disease.

Related product monographs

Document Type Information Source  
 ARICEPT Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 ARICEPT Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 AXURA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 CONSION XL Prolonged-release capsule, hard MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 DONECEPT Film-coated tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 DOZEPT Film-coated tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 EBIXA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 EBIXA Oral solution MPI, EU: SmPC European Medicines Agency (EU)
 EXELON Hard capsule MPI, EU: SmPC European Medicines Agency (EU)
 EXELON Transdermal patch MPI, EU: SmPC European Medicines Agency (EU)
 GALSYA Prolonged-release capsule, hard MPI, EU: SmPC Health Products Regulatory Authority (IE)
 KISUNLA Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 LEQEMBI Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 NEMDATINE Film-coated tablets MPI, EU: SmPC European Medicines Agency (EU)
 NIMVASTID Hard capsule MPI, EU: SmPC European Medicines Agency (EU)